Compare JOE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | NAMS |
|---|---|---|
| Founded | 1936 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | N/A | N/A |
| Metric | JOE | NAMS |
|---|---|---|
| Price | $67.37 | $32.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $47.38 |
| AVG Volume (30 Days) | 182.7K | ★ 661.5K |
| Earning Date | 02-25-2026 | 02-25-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | ★ 53.79 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $488,689,000.00 | $35,243,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.46 |
| P/E Ratio | $37.71 | ★ N/A |
| Revenue Growth | ★ 26.89 | 4.91 |
| 52 Week Low | $40.19 | $14.06 |
| 52 Week High | $68.48 | $42.00 |
| Indicator | JOE | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 69.64 | 49.87 |
| Support Level | $64.42 | $31.77 |
| Resistance Level | $67.35 | $33.80 |
| Average True Range (ATR) | 1.60 | 1.42 |
| MACD | 0.19 | 0.16 |
| Stochastic Oscillator | 99.46 | 62.87 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.